Logo

MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

Share this

MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

Shots:

  • MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of dual regimen for multiple cancer indications in a P-I study
  • The collaboration will further explore the therapeutic potential of combination therapy- TJC4 with Keytruda across multiple tumors
  • I-Mab’s TJC4 is an anti-CD47 mAb- recognizes the unique epitope on CD47- thus avoid the binding to RBCs- under clinical development in the US and has received NMPA’s IND approval in China

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Plantadoce


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions